Identification and functional consequences of a recurrent NLRP12 missense mutation in periodic fever syndromes

Objective To gain insight into the molecular bases of genetically unexplained periodic fever syndromes (PFS) by screening NLRP12, a gene in which only a nonsense and a splice site mutation have so far been identified, and to assess the functional consequences of the identified missense variation. Me...

Full description

Saved in:
Bibliographic Details
Published inArthritis & rheumatology (Hoboken, N.J.) Vol. 63; no. 5; pp. 1459 - 1464
Main Authors Jéru, Isabelle, Le Borgne, Gaëlle, Cochet, Emmanuelle, Hayrapetyan, Hasmik, Duquesnoy, Philippe, Grateau, Gilles, Morali, Alain, Sarkisian, Tamara, Amselem, Serge
Format Journal Article
LanguageEnglish
Published Hoboken Wiley Subscription Services, Inc., A Wiley Company 01.05.2011
Wiley
Wiley Subscription Services, Inc
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Objective To gain insight into the molecular bases of genetically unexplained periodic fever syndromes (PFS) by screening NLRP12, a gene in which only a nonsense and a splice site mutation have so far been identified, and to assess the functional consequences of the identified missense variation. Methods NLRP12 was screened for mutations by direct sequencing. Functional assays were performed in HEK 293T cells stably expressing the proapoptotic protein ASC and procaspase 1, in order to determine the effects of normal and mutated NLRP12 proteins on speck formation, caspase 1 signaling, and NF‐κB activation. Results A heterozygous NLRP12 missense mutation involving a CpG site (c.1054C>T; p.Arg352Cys) was identified in exon 3, which encodes the nucleotide‐binding site (NBS) of the protein, in 2 patients from different countries and carrying different NLRP12 haplotypes. The mutation, which does not alter the inhibitory effect of NLRP12 on NF‐κB activation, increases speck formation and activates caspase 1 signaling. To define this new class of PFS, we propose the term NLRP12‐associated disorders (NLRP12AD). Conclusion Given the rarity of known NLRP12‐associated disorders, the identification of this NLRP12 molecular defect contributes to the delineation of the clinical spectrum associated with mutations in this gene and highlights the importance of screening NLRP12 in patients presenting with unexplained PFS. This study also demonstrates, by means of functional assays, the deleterious effect of this recurrent missense mutation; the gain of function for speck formation and caspase 1 signaling associated with this NBS mutation is consistent with the inflammatory phenotype of PFS.
AbstractList Objective To gain insight into the molecular bases of genetically unexplained periodic fever syndromes (PFS) by screening NLRP12, a gene in which only a nonsense and a splice site mutation have so far been identified, and to assess the functional consequences of the identified missense variation. Methods NLRP12 was screened for mutations by direct sequencing. Functional assays were performed in HEK 293T cells stably expressing the proapoptotic protein ASC and procaspase 1, in order to determine the effects of normal and mutated NLRP12 proteins on speck formation, caspase 1 signaling, and NF‐κB activation. Results A heterozygous NLRP12 missense mutation involving a CpG site (c.1054C>T; p.Arg352Cys) was identified in exon 3, which encodes the nucleotide‐binding site (NBS) of the protein, in 2 patients from different countries and carrying different NLRP12 haplotypes. The mutation, which does not alter the inhibitory effect of NLRP12 on NF‐κB activation, increases speck formation and activates caspase 1 signaling. To define this new class of PFS, we propose the term NLRP12‐associated disorders (NLRP12AD). Conclusion Given the rarity of known NLRP12‐associated disorders, the identification of this NLRP12 molecular defect contributes to the delineation of the clinical spectrum associated with mutations in this gene and highlights the importance of screening NLRP12 in patients presenting with unexplained PFS. This study also demonstrates, by means of functional assays, the deleterious effect of this recurrent missense mutation; the gain of function for speck formation and caspase 1 signaling associated with this NBS mutation is consistent with the inflammatory phenotype of PFS.
To gain insight into the molecular bases of genetically unexplained periodic fever syndromes (PFS) by screening NLRP12, a gene in which only a nonsense and a splice site mutation have so far been identified, and to assess the functional consequences of the identified missense variation. NLRP12 was screened for mutations by direct sequencing. Functional assays were performed in HEK 293T cells stably expressing the proapoptotic protein ASC and procaspase 1, in order to determine the effects of normal and mutated NLRP12 proteins on speck formation, caspase 1 signaling, and NF-κB activation. A heterozygous NLRP12 missense mutation involving a CpG site (c.1054C>T; p.Arg352Cys) was identified in exon 3, which encodes the nucleotide-binding site (NBS) of the protein, in 2 patients from different countries and carrying different NLRP12 haplotypes. The mutation, which does not alter the inhibitory effect of NLRP12 on NF-κB activation, increases speck formation and activates caspase 1 signaling. To define this new class of PFS, we propose the term NLRP12-associated disorders (NLRP12AD). Given the rarity of known NLRP12-associated disorders, the identification of this NLRP12 molecular defect contributes to the delineation of the clinical spectrum associated with mutations in this gene and highlights the importance of screening NLRP12 in patients presenting with unexplained PFS. This study also demonstrates, by means of functional assays, the deleterious effect of this recurrent missense mutation; the gain of function for speck formation and caspase 1 signaling associated with this NBS mutation is consistent with the inflammatory phenotype of PFS.
Objective: To gain insight into the molecular bases of genetically unexplained periodic fever syndromes (PFS) by screening NLRP12, a gene in which only a nonsense and a splice site mutation have so far been identified, and to assess the functional consequences of the identified missense variation.Methods: NLRP12 was screened for mutations by direct sequencing. Functional assays were performed in HEK 293T cells stably expressing the proapoptotic protein ASC and procaspase 1, in order to determine the effects of normal and mutated NLRP12 proteins on speck formation, caspase 1 signaling, and NF-κB activation.Results: A heterozygous NLRP12 missense mutation involving a CpG site (c.1054C>T; p.Arg352Cys) was identified in exon 3, which encodes the nucleotide-binding site (NBS) of the protein, in 2 patients from different countries and carrying different NLRP12 haplotypes. The mutation, which does not alter the inhibitory effect of NLRP12 on NF-κB activation, increases speck formation and activates caspase 1 signaling. To define this new class of PFS, we propose the term NLRP12-associated disorders (NLRP12AD).Conclusion: Given the rarity of known NLRP12-associated disorders, the identification of this NLRP12 molecular defect contributes to the delineation of the clinical spectrum associated with mutations in this gene and highlights the importance of screening NLRP12 in patients presenting with unexplained PFS. This study also demonstrates, by means of functional assays, the deleterious effect of this recurrent missense mutation; the gain of function for speck formation and caspase 1 signaling associated with this NBS mutation is consistent with the inflammatory phenotype of PFS.
OBJECTIVETo gain insight into the molecular bases of genetically unexplained periodic fever syndromes (PFS) by screening NLRP12, a gene in which only a nonsense and a splice site mutation have so far been identified, and to assess the functional consequences of the identified missense variation.METHODSNLRP12 was screened for mutations by direct sequencing. Functional assays were performed in HEK 293T cells stably expressing the proapoptotic protein ASC and procaspase 1, in order to determine the effects of normal and mutated NLRP12 proteins on speck formation, caspase 1 signaling, and NF-κB activation.RESULTSA heterozygous NLRP12 missense mutation involving a CpG site (c.1054C>T; p.Arg352Cys) was identified in exon 3, which encodes the nucleotide-binding site (NBS) of the protein, in 2 patients from different countries and carrying different NLRP12 haplotypes. The mutation, which does not alter the inhibitory effect of NLRP12 on NF-κB activation, increases speck formation and activates caspase 1 signaling. To define this new class of PFS, we propose the term NLRP12-associated disorders (NLRP12AD).CONCLUSIONGiven the rarity of known NLRP12-associated disorders, the identification of this NLRP12 molecular defect contributes to the delineation of the clinical spectrum associated with mutations in this gene and highlights the importance of screening NLRP12 in patients presenting with unexplained PFS. This study also demonstrates, by means of functional assays, the deleterious effect of this recurrent missense mutation; the gain of function for speck formation and caspase 1 signaling associated with this NBS mutation is consistent with the inflammatory phenotype of PFS.
Objective To gain insight into the molecular bases of genetically unexplained periodic fever syndromes (PFS) by screening NLRP12, a gene in which only a nonsense and a splice site mutation have so far been identified, and to assess the functional consequences of the identified missense variation. Methods NLRP12 was screened for mutations by direct sequencing. Functional assays were performed in HEK 293T cells stably expressing the proapoptotic protein ASC and procaspase 1, in order to determine the effects of normal and mutated NLRP12 proteins on speck formation, caspase 1 signaling, and NF-[kappa]B activation. Results A heterozygous NLRP12 missense mutation involving a CpG site (c.1054C>T; p.Arg352Cys) was identified in exon 3, which encodes the nucleotide-binding site (NBS) of the protein, in 2 patients from different countries and carrying different NLRP12 haplotypes. The mutation, which does not alter the inhibitory effect of NLRP12 on NF-[kappa]B activation, increases speck formation and activates caspase 1 signaling. To define this new class of PFS, we propose the term NLRP12-associated disorders (NLRP12AD). Conclusion Given the rarity of known NLRP12-associated disorders, the identification of this NLRP12 molecular defect contributes to the delineation of the clinical spectrum associated with mutations in this gene and highlights the importance of screening NLRP12 in patients presenting with unexplained PFS. This study also demonstrates, by means of functional assays, the deleterious effect of this recurrent missense mutation; the gain of function for speck formation and caspase 1 signaling associated with this NBS mutation is consistent with the inflammatory phenotype of PFS. [PUBLICATION ABSTRACT]
Objective To gain insight into the molecular bases of genetically unexplained periodic fever syndromes (PFS) by screening NLRP12, a gene in which only a nonsense and a splice site mutation have so far been identified, and to assess the functional consequences of the identified missense variation. Methods NLRP12 was screened for mutations by direct sequencing. Functional assays were performed in HEK 293T cells stably expressing the proapoptotic protein ASC and procaspase 1, in order to determine the effects of normal and mutated NLRP12 proteins on speck formation, caspase 1 signaling, and NF- Delta *kB activation. Results A heterozygous NLRP12 missense mutation involving a CpG site (c.1054C>T; p.Arg352Cys) was identified in exon 3, which encodes the nucleotide-binding site (NBS) of the protein, in 2 patients from different countries and carrying different NLRP12 haplotypes. The mutation, which does not alter the inhibitory effect of NLRP12 on NF- Delta *kB activation, increases speck formation and activates caspase 1 signaling. To define this new class of PFS, we propose the term NLRP12-associated disorders (NLRP12AD). Conclusion Given the rarity of known NLRP12-associated disorders, the identification of this NLRP12 molecular defect contributes to the delineation of the clinical spectrum associated with mutations in this gene and highlights the importance of screening NLRP12 in patients presenting with unexplained PFS. This study also demonstrates, by means of functional assays, the deleterious effect of this recurrent missense mutation; the gain of function for speck formation and caspase 1 signaling associated with this NBS mutation is consistent with the inflammatory phenotype of PFS.
Author Morali, Alain
Le Borgne, Gaëlle
Duquesnoy, Philippe
Cochet, Emmanuelle
Jéru, Isabelle
Sarkisian, Tamara
Hayrapetyan, Hasmik
Grateau, Gilles
Amselem, Serge
Author_xml – sequence: 1
  givenname: Isabelle
  surname: Jéru
  fullname: Jéru, Isabelle
– sequence: 2
  givenname: Gaëlle
  surname: Le Borgne
  fullname: Le Borgne, Gaëlle
– sequence: 3
  givenname: Emmanuelle
  surname: Cochet
  fullname: Cochet, Emmanuelle
– sequence: 4
  givenname: Hasmik
  surname: Hayrapetyan
  fullname: Hayrapetyan, Hasmik
– sequence: 5
  givenname: Philippe
  surname: Duquesnoy
  fullname: Duquesnoy, Philippe
– sequence: 6
  givenname: Gilles
  surname: Grateau
  fullname: Grateau, Gilles
– sequence: 7
  givenname: Alain
  surname: Morali
  fullname: Morali, Alain
– sequence: 8
  givenname: Tamara
  surname: Sarkisian
  fullname: Sarkisian, Tamara
– sequence: 9
  givenname: Serge
  surname: Amselem
  fullname: Amselem, Serge
  email: serge.amselem@trs.aphp.fr
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=24218763$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/21538323$$D View this record in MEDLINE/PubMed
https://inserm.hal.science/inserm-03889764$$DView record in HAL
BookMark eNp90V9rFDEQAPAgFXutPvgFJCCigttmks0m93iU1hYOlVKfQzY7iym7yZncVu7bm3PPCoI-hSG_zJ_MCTkKMSAhL4GdAWP83KbtmWC8hidkAZIvKwYCjsiCMVZXQi7hmJzkfF9CLqR4Ro45SKEFFwsSbjoMW997Z7c-BmpDR_spuH1gB-piyPh9wuAw09hTSxO6KaXyhn5a334BTkefMxZFx2k75_CBbjD52HlHe3zARPMudCmOmJ-Tp70dMr44nKfk69Xl3cV1tf788eZita6cBA2VaFvXt6K1HVMapW06ROm4dj1vRIlaJ51G0ZRb1UmppNJtuYDGWsG6phGn5MOc95sdzCb50aadidab69Xa-NJtGg0TWi9VUz9A4W9nvkmxTJu3pkzlcBhswDhlo5ta6RqYKvLdfyVwoYEtuZaFvv6L3scplV8tSoJitVa8Lur9rFyKOSfsH9sFZvbbNWW75td2i311yDi1I3aP8vc6C3hzADY7O_TJBufzH1dz0KrZu_PZ_fAD7v5d0axu7-bSPwFPrryr
CODEN ARHEAW
CitedBy_id crossref_primary_10_3390_life13112131
crossref_primary_10_1016_j_immuni_2015_03_006
crossref_primary_10_1146_annurev_immunol_032414_112227
crossref_primary_10_1007_s00296_018_4092_3
crossref_primary_10_1111_cge_13789
crossref_primary_10_1080_1744666X_2017_1280396
crossref_primary_10_1016_j_berh_2012_07_009
crossref_primary_10_3109_14397595_2013_843755
crossref_primary_10_1007_s10620_019_05525_6
crossref_primary_10_1136_rmdopen_2023_003598
crossref_primary_10_1038_mi_2015_80
crossref_primary_10_1016_j_ejphar_2023_175995
crossref_primary_10_1002_art_30378
crossref_primary_10_1101_cshperspect_a028563
crossref_primary_10_1084_jem_20141091
crossref_primary_10_1016_j_rceng_2016_10_001
crossref_primary_10_3389_fimmu_2017_00043
crossref_primary_10_1073_pnas_1317643111
crossref_primary_10_1016_j_pharmthera_2018_02_011
crossref_primary_10_1186_s12974_022_02425_x
crossref_primary_10_1189_jlb_3RU0514_265RR
crossref_primary_10_1016_j_clim_2024_110278
crossref_primary_10_1126_scisignal_abg8145
crossref_primary_10_1016_j_rce_2016_08_004
crossref_primary_10_1093_rheumatology_kez294
crossref_primary_10_1155_2024_5573272
crossref_primary_10_1111_imr_12898
crossref_primary_10_1111_febs_16203
crossref_primary_10_1007_s10067_014_2721_0
crossref_primary_10_1007_s12519_019_00294_8
crossref_primary_10_1371_journal_ppat_1003885
crossref_primary_10_3389_fgene_2021_631340
crossref_primary_10_3390_molecules25194572
crossref_primary_10_1007_s12026_012_8272_z
crossref_primary_10_1016_j_semarthrit_2019_05_002
crossref_primary_10_1007_s00018_012_0989_2
crossref_primary_10_1016_j_immuni_2012_07_006
crossref_primary_10_1111_jdv_18969
crossref_primary_10_3389_fmed_2023_1257045
crossref_primary_10_1007_s12016_017_8613_8
crossref_primary_10_1186_s43141_021_00268_2
crossref_primary_10_1016_j_clim_2014_07_003
crossref_primary_10_1146_annurev_pathol_012414_040431
crossref_primary_10_1007_s10067_016_3410_y
crossref_primary_10_1038_srep10200
crossref_primary_10_5713_ajas_2013_13087
crossref_primary_10_3109_13816810_2012_695421
crossref_primary_10_1007_s00296_018_4002_8
crossref_primary_10_3389_fimmu_2017_00344
crossref_primary_10_1016_j_cytogfr_2016_11_001
crossref_primary_10_1080_14397595_2020_1784542
crossref_primary_10_1002_lio2_28
crossref_primary_10_1016_j_jaip_2023_05_040
crossref_primary_10_1080_10408363_2018_1488805
crossref_primary_10_1097_BOR_0b013e32834dd2d5
crossref_primary_10_1038_ni_3777
crossref_primary_10_2177_jsci_34_329
crossref_primary_10_1371_journal_pgen_1008180
crossref_primary_10_1155_2013_939847
crossref_primary_10_1111_j_1600_065X_2011_01050_x
crossref_primary_10_1186_s13256_022_03404_9
crossref_primary_10_1007_s10067_020_05492_8
crossref_primary_10_1073_pnas_1905261116
crossref_primary_10_1042_CS20171498
crossref_primary_10_1097_MIB_0000000000000151
crossref_primary_10_1093_rheumatology_keaa304
crossref_primary_10_3389_fimmu_2021_827815
crossref_primary_10_1186_s12969_022_00669_8
Cites_doi 10.1086/341357
10.1038/sj.cdd.4401734
10.1074/jbc.M502820200
10.1002/art.27326
10.1016/j.cell.2007.07.009
10.1073/pnas.0708616105
10.1038/nm1201-1291
10.1074/jbc.M203915200
10.1146/annurev.immunol.14.1.649
10.1074/jbc.274.48.33835
10.1128/MCB.01468-07
10.1002/art.21618
ContentType Journal Article
Copyright Copyright © 2011 by the American College of Rheumatology
2015 INIST-CNRS
Copyright © 2011 by the American College of Rheumatology.
Distributed under a Creative Commons Attribution 4.0 International License
Copyright_xml – notice: Copyright © 2011 by the American College of Rheumatology
– notice: 2015 INIST-CNRS
– notice: Copyright © 2011 by the American College of Rheumatology.
– notice: Distributed under a Creative Commons Attribution 4.0 International License
DBID IQODW
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7QL
7QP
7T5
7TM
7U7
C1K
H94
K9.
8FD
FR3
P64
RC3
7X8
1XC
DOI 10.1002/art.30241
DatabaseName Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
Bacteriology Abstracts (Microbiology B)
Calcium & Calcified Tissue Abstracts
Immunology Abstracts
Nucleic Acids Abstracts
Toxicology Abstracts
Environmental Sciences and Pollution Management
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Technology Research Database
Engineering Research Database
Biotechnology and BioEngineering Abstracts
Genetics Abstracts
MEDLINE - Academic
Hyper Article en Ligne (HAL)
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
Toxicology Abstracts
Bacteriology Abstracts (Microbiology B)
Nucleic Acids Abstracts
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Immunology Abstracts
Calcium & Calcified Tissue Abstracts
Environmental Sciences and Pollution Management
Genetics Abstracts
Engineering Research Database
Technology Research Database
Biotechnology and BioEngineering Abstracts
MEDLINE - Academic
DatabaseTitleList
MEDLINE

MEDLINE - Academic
Toxicology Abstracts
Genetics Abstracts
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1529-0131
2326-5205
2326-5191
EndPage 1464
ExternalDocumentID oai_HAL_inserm_03889764v1
3277865791
10_1002_art_30241
21538323
24218763
ART30241
Genre article
Research Support, Non-U.S. Gov't
Journal Article
GrantInformation_xml – fundername: Association François Aupetit
– fundername: Agence Nationale pour la Recherche
  funderid: 06‐MRAR‐010‐02
– fundername: European Union Sixth Framework Programme (EURAMY project grant)
  funderid: LSHM‐CT‐2006‐037525
– fundername: International Science and Technology Center
  funderid: A‐1580
GroupedDBID ---
.3N
.55
.GA
.GJ
.Y3
05W
10A
1CY
1KJ
1L6
1OB
1OC
1ZS
23N
24P
31~
33P
3O-
3WU
4.4
4ZD
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52W
52X
53G
5GY
5RE
66C
6J9
6P2
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A01
A03
AAEVG
AAHHS
AAKAS
AANLZ
AAQQT
AAWTL
AAXRX
AAZKR
ABCQN
ABCUV
ABEML
ABIJN
ABJNI
ABQWH
ABXGK
ACAHQ
ACBWZ
ACCFJ
ACCZN
ACFBH
ACGFO
ACMXC
ACPOU
ACSCC
ACXBN
ACXQS
ADBTR
ADEOM
ADIZJ
ADMGS
ADOZA
ADZCM
ADZOD
AEEZP
AEIGN
AEIMD
AEQDE
AEUQT
AEUYR
AFBPY
AFFNX
AFFPM
AFGKR
AFPWT
AFZJQ
AHBTC
AI.
AIACR
AITYG
AIURR
AIWBW
AJBDE
ALMA_UNASSIGNED_HOLDINGS
ALUQN
AMBMR
AMYDB
ASPBG
ATUGU
AVWKF
AZFZN
BDRZF
BROTX
BRXPI
BY8
C45
CS3
D-6
D-7
D-E
D-F
DCZOG
DPXWK
DR2
DRFUL
DRMAN
DRSTM
EBS
EJD
EMOBN
EX3
F00
F01
F04
F5P
FEDTE
G-S
G.N
GNP
GODZA
HBH
HF~
HGLYW
HHY
HHZ
HVGLF
HZ~
IX1
J5H
JPC
KQQ
LATKE
LAW
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LSO
LUTES
LW6
LYRES
M65
MEWTI
MJL
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N4W
N9A
NNB
OIG
OK1
OVD
P2P
P2W
P2X
P2Z
P4B
P4D
Q11
QB0
QRW
RGB
RIWAO
RJQFR
ROL
RWI
RX1
RXW
RYL
SAMSI
SJN
SUPJJ
SV3
TAE
TEORI
TWZ
UB1
V2E
V8K
V9Y
VH1
W8V
WH7
WIB
WIH
WIJ
WIK
WIN
WJL
WOW
WQJ
WRC
WUP
WXI
WXSBR
X6Y
X7M
XG1
XPP
XV2
YFH
YOC
ZGI
ZXP
ZZTAW
~IA
~WT
08R
AAUGY
AAVGM
ABHUG
ABPTK
ABWRO
ACXME
ADAWD
ADDAD
AFVGU
AGJLS
IQODW
ZA5
CGR
CUY
CVF
ECM
EIF
NPM
AAMNL
AAYXX
ACRPL
ACYXJ
CITATION
0R~
3SF
52U
52V
5VS
7QL
7QP
7T5
7TM
7U7
AAESR
AASGY
ABLJU
ABPVW
ACGFS
ACGOF
ACIWK
ACPRK
ADBBV
ADKYN
ADXAS
ADZMN
AENEX
AFRAH
AHMBA
ALAGY
AZVAB
BFHJK
BHBCM
BMXJE
C1K
DIK
FUBAC
H94
K9.
KBYEO
NF~
O66
O9-
PQQKQ
WBKPD
WHWMO
WOHZO
WVDHM
8FD
FR3
P64
RC3
7X8
1XC
YCJ
ID FETCH-LOGICAL-c5181-3bbcfb3bad078e5a6dee5c28cf263a6dbc5c8e360787d557578b63a16aa30d663
IEDL.DBID DR2
ISSN 0004-3591
2326-5191
1529-0131
2326-5205
IngestDate Tue Oct 15 15:45:36 EDT 2024
Tue Dec 03 23:21:19 EST 2024
Wed Dec 04 11:37:41 EST 2024
Thu Oct 10 22:11:44 EDT 2024
Fri Dec 06 01:30:35 EST 2024
Sat Sep 28 08:00:44 EDT 2024
Sun Oct 22 16:05:28 EDT 2023
Sat Aug 24 00:54:14 EDT 2024
IsPeerReviewed true
IsScholarly true
Issue 5
Keywords Relapse
Missense mutation
Diseases of the osteoarticular system
Familial mediterranean fever
Rheumatology
Hereditary periodic fever
Identification
Genetic disease
Inflammatory disease
Language English
License CC BY 4.0
Copyright © 2011 by the American College of Rheumatology.
http://onlinelibrary.wiley.com/termsAndConditions#vor
Distributed under a Creative Commons Attribution 4.0 International License: http://creativecommons.org/licenses/by/4.0
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c5181-3bbcfb3bad078e5a6dee5c28cf263a6dbc5c8e360787d557578b63a16aa30d663
Notes Dr. Grateau has received honoraria from Novartis (less than $10,000).
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Article-1
ObjectType-Feature-2
ORCID 0000-0001-9506-3968
PMID 21538323
PQID 1517048724
PQPubID 946334
PageCount 6
ParticipantIDs hal_primary_oai_HAL_inserm_03889764v1
proquest_miscellaneous_864784107
proquest_miscellaneous_1238109285
proquest_journals_1517048724
crossref_primary_10_1002_art_30241
pubmed_primary_21538323
pascalfrancis_primary_24218763
wiley_primary_10_1002_art_30241_ART30241
PublicationCentury 2000
PublicationDate May 2011
PublicationDateYYYYMMDD 2011-05-01
PublicationDate_xml – month: 05
  year: 2011
  text: May 2011
PublicationDecade 2010
PublicationPlace Hoboken
PublicationPlace_xml – name: Hoboken
– name: Hoboken , NJ
– name: United States
– name: Atlanta
PublicationTitle Arthritis & rheumatology (Hoboken, N.J.)
PublicationTitleAlternate Arthritis Rheum
PublicationYear 2011
Publisher Wiley Subscription Services, Inc., A Wiley Company
Wiley
Wiley Subscription Services, Inc
Publisher_xml – name: Wiley Subscription Services, Inc., A Wiley Company
– name: Wiley
– name: Wiley Subscription Services, Inc
References 2005; 280
2009; 68
2001; 7
2006; 13
2006; 54
2007; 130
2002; 277
2008; 28
1999; 274
2008; 105
2002; 71
1996; 14
2010; 62
e_1_2_7_5_2
e_1_2_7_4_2
e_1_2_7_3_2
e_1_2_7_2_2
e_1_2_7_9_2
e_1_2_7_8_2
e_1_2_7_7_2
e_1_2_7_6_2
e_1_2_7_13_2
e_1_2_7_12_2
e_1_2_7_11_2
e_1_2_7_10_2
Gattorno M (e_1_2_7_14_2) 2009; 68
References_xml – volume: 105
  start-page: 1614
  year: 2008
  end-page: 9
  article-title: Mutations in NALP12 cause hereditary periodic fever syndromes
  publication-title: Proc Natl Acad Sci U S A
– volume: 28
  start-page: 1841
  year: 2008
  end-page: 50
  article-title: ATP binding by Monarch‐1/NLRP12 is critical for its inhibitory function
  publication-title: Mol Cell Biol
– volume: 62
  start-page: 1176
  year: 2010
  end-page: 85
  article-title: Functional consequences of a germline mutation in the leucine‐rich repeat domain of NLRP3 identified in an atypical autoinflammatory disorder
  publication-title: Arthritis Rheum
– volume: 13
  start-page: 236
  year: 2006
  end-page: 49
  article-title: Cryopyrin and pyrin activate caspase‐1, but not NF‐κB, via ASC oligomerization
  publication-title: Cell Death Differ
– volume: 68
  start-page: 83
  issue: Suppl 13
  year: 2009
  article-title: Clinical and immunological characterization of an Italian family with a novel NALP12 mutation
  publication-title: Ann Rheum Dis
– volume: 7
  start-page: 1291
  year: 2001
  end-page: 7
  article-title: Possible new role for NF‐βB in the resolution of inflammation
  publication-title: Nat Med
– volume: 71
  start-page: 198
  year: 2002
  end-page: 203
  article-title: Chronic infantile neurological cutaneous and articular syndrome is caused by mutations in CIAS1, a gene highly expressed in polymorphonuclear cells and chondrocytes
  publication-title: Am J Hum Genet
– volume: 274
  start-page: 33835
  year: 1999
  end-page: 8
  article-title: ASC, a novel 22‐kDa protein, aggregates during apoptosis of human promyelocytic leukemia HL‐60 cells
  publication-title: J Biol Chem
– volume: 14
  start-page: 649
  year: 1996
  end-page: 83
  article-title: The NF‐κB and IκB proteins: new discoveries and insights
  publication-title: Annu Rev Immunol
– volume: 130
  start-page: 918
  year: 2007
  end-page: 31
  article-title: NF‐κB is a negative regulator of IL‐1β secretion as revealed by genetic and pharmacological inhibition of IKKβ
  publication-title: Cell
– volume: 280
  start-page: 39914
  year: 2005
  end-page: 24
  article-title: The CATERPILLER protein Monarch‐1 is an antagonist of Toll‐like receptor‐, tumor necrosis factor α‐, and Mycobacterium tuberculosis‐induced pro‐inflammatory signals
  publication-title: J Biol Chem
– volume: 54
  start-page: 508
  year: 2006
  end-page: 14
  article-title: PYPAF1 nonsense mutation in a patient with an unusual autoinflammatory syndrome: role of PYPAF1 in inflammation
  publication-title: Arthritis Rheum
– volume: 277
  start-page: 29874
  year: 2002
  end-page: 80
  article-title: PYPAF7, a novel PYRIN‐containing Apaf1‐like protein that regulates activation of NF‐κB and caspase‐1‐dependent cytokine processing
  publication-title: J Biol Chem
– ident: e_1_2_7_6_2
  doi: 10.1086/341357
– ident: e_1_2_7_7_2
  doi: 10.1038/sj.cdd.4401734
– volume: 68
  start-page: 83
  issue: 13
  year: 2009
  ident: e_1_2_7_14_2
  article-title: Clinical and immunological characterization of an Italian family with a novel NALP12 mutation
  publication-title: Ann Rheum Dis
  contributor:
    fullname: Gattorno M
– ident: e_1_2_7_4_2
  doi: 10.1074/jbc.M502820200
– ident: e_1_2_7_8_2
  doi: 10.1002/art.27326
– ident: e_1_2_7_11_2
  doi: 10.1016/j.cell.2007.07.009
– ident: e_1_2_7_2_2
  doi: 10.1073/pnas.0708616105
– ident: e_1_2_7_12_2
  doi: 10.1038/nm1201-1291
– ident: e_1_2_7_3_2
  doi: 10.1074/jbc.M203915200
– ident: e_1_2_7_10_2
  doi: 10.1146/annurev.immunol.14.1.649
– ident: e_1_2_7_5_2
  doi: 10.1074/jbc.274.48.33835
– ident: e_1_2_7_9_2
  doi: 10.1128/MCB.01468-07
– ident: e_1_2_7_13_2
  doi: 10.1002/art.21618
SSID ssj0002353
ssj0000970605
Score 2.3763335
Snippet Objective To gain insight into the molecular bases of genetically unexplained periodic fever syndromes (PFS) by screening NLRP12, a gene in which only a...
To gain insight into the molecular bases of genetically unexplained periodic fever syndromes (PFS) by screening NLRP12, a gene in which only a nonsense and a...
Objective To gain insight into the molecular bases of genetically unexplained periodic fever syndromes (PFS) by screening NLRP12, a gene in which only a...
OBJECTIVETo gain insight into the molecular bases of genetically unexplained periodic fever syndromes (PFS) by screening NLRP12, a gene in which only a...
Objective: To gain insight into the molecular bases of genetically unexplained periodic fever syndromes (PFS) by screening NLRP12, a gene in which only a...
SourceID hal
proquest
crossref
pubmed
pascalfrancis
wiley
SourceType Open Access Repository
Aggregation Database
Index Database
Publisher
StartPage 1459
SubjectTerms Apoptosis
Binding sites
Biological and medical sciences
Caspase-1
CpG islands
Diseases of the osteoarticular system
Exons
Fever
Genetics
Haplotypes
Hereditary Autoinflammatory Diseases - genetics
Human genetics
Humans
Inflammatory joint diseases
Intracellular Signaling Peptides and Proteins - genetics
Life Sciences
Malformations and congenital and or hereditary diseases involving bones. Joint deformations
Medical sciences
Missense mutation
Mutation
Mutation, Missense - genetics
Phenotype
Speck
Title Identification and functional consequences of a recurrent NLRP12 missense mutation in periodic fever syndromes
URI https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fart.30241
https://www.ncbi.nlm.nih.gov/pubmed/21538323
https://www.proquest.com/docview/1517048724
https://search.proquest.com/docview/1238109285
https://search.proquest.com/docview/864784107
https://inserm.hal.science/inserm-03889764
Volume 63
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3da9RAEB9qH0QQrd_R9lhFwZdck91sPvCptJZT2yLFQh-EsJ9Y5HLlPnzwr3cmm-Q8sSC-3bETlp2dyfx2duYXgNc-S6w2uY4LpXWc-dTGynAfm0Qa6vw0vqR-59OzfHKRfbyUl1vwru-FCfwQQ8KNPKN9X5ODK73YX5OGombHAiMMHX1SUVA539H5mjqKi46BkjL_skp7VqGE7w9PbsSiW9-oEvLutVqgcnz4qsXfYOcmim3D0PF9-NovIFSffB-vlnpsfv7B7fifK9yBex08ZQfBnh7Almsewu3T7gL-ETShsdd3mT6mGssoNIaMIjO_1WazmWeKzSmfTwxQ7Ozk_HPK2ZQKAFCKTVehCoBdNYzolmc4B_MOXYv1NAqLx3Bx_P7L4STuPtkQG4lYIRZaG6-FVhahh5Mqt85Jw0vjeS7wnzbSlE7kOFpYKYlMX-NAmislEovo5wlsN7PGPQNmi7wyrkhtRS0sSlaitCkalleeey91BK_6zauvAzNHHTiYeY2aq1vNRfAGt3UYJy7tycFJfYXLnE9rYsJBOJb9QLnRxsYPT9CNOZH2RbDbW0LdefmiRrRU4Buw4FkEL4dh1CNduqjGzVYoQ5goqXgpI2A3yJTU8JvhQTyCp8HI1vNTRBIc53_bmsrNS63xANT-eP7voi_gTsiRUwHnLmwv5yu3hyBrqUfoTR8-jVqf-gWf5STl
link.rule.ids 230,314,780,784,885,1375,27924,27925,46294,46718
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3ra9RAEB9qBRXE9yNa6yoKfsk12WTzAL8UtZx6d0hpoV9k2ScWuVy5hx_8653JJneeWBC_3bETlp2dyfx2duYXgFc-T6w2hY5LpXWc-9TGynAfm0QY6vw0vqJ-5_GkGJ7mn87E2Q687XthAj_EOuFGntG-r8nBKSF9sGENRdUOMgwxePa5iu6eUkHX--MNeRTPOg5Kyv2LOu15hRJ-sH50Kxpd-Ua1kDcv1ALV48N3Lf4GPLdxbBuIjm7D134Jof7k-2C11APz8w92x_9d4x241SFUdhhM6i7suOYeXBt3d_D3oQm9vb5L9jHVWEbRMSQVmfmtPJvNPFNsTil9IoFik9Hxl5SzKdUAoBSbrkIhADtvGDEuz3AO5h16F-uZFBYP4PTow8m7Ydx9tSE2AuFCnGltvM60sog-nFCFdU4YXhnPiwz_aSNM5bICR0srBPHpaxxIC6WyxCIAegi7zaxxj4HZsqiNK1NbUxeLEnVW2RRtyyvPvRc6gpf97smLQM4hAw0zl6g52Wougte4r-txotMeHo7kOS5zPpVEhoOILP-BcvtbO79-gi7Nibcvgr3eFGTn6AuJgKnEl2DJ8wherIdRj3Tvoho3W6EMwaKk5pWIgF0iU1HPb45n8QgeBSvbzE9BKeM4_5vWVi5fqsQzUPvjyb-LPofrw5PxSI4-Tj4_hRshZU71nHuwu5yv3DPEXEu937rWL_guKA0
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3da9RAEB9qhSKI39Voraso-JJrssnmA5-K9Tj1epRioQ9C2E8scrnjPnzwr3cmm-Q8sSC-3bETlp2dyfx2duYXgNcujYzSmQpzqVSYutiEUnMX6kho6vzUrqB-59NJNrpIP12Kyx141_XCeH6IPuFGntG8r8nB58YdbUhDUbODBCMMHn1uphkviTj_5HzDHcWTloKSUv-ijDtaoYgf9Y9uBaMb36gU8vZcLlE7zn_W4m-4cxvGNnFoeBe-divw5SffB-uVGuiff5A7_ucS78GdFp-yY29Q92HH1g9g77S9gX8Ite_sdW2qj8naMIqNPqXI9G_F2WzmmGQLSugTBRSbjM_PYs6mVAGAUmy69mUA7KpmxLc8wzmYs-hbrONRWD6Ci-GHL-9HYfvNhlALBAthopR2KlHSIPawQmbGWqF5oR3PEvyntNCFTTIczY0QxKavcCDOpEwig_BnH3brWW2fADN5Vmqbx6akHhYpyqQwMVqWk447J1QAr7rNq-aemqPyJMy8Qs1VjeYCeIPb2o8TmfboeFxd4TIX04qocBCPpT9Q7nBr4_sn6MqcWPsCOOgsoWrdfFkhXMrxFZjzNICX_TDqkW5dZG1na5QhUBSVvBABsGtkCur4TfEkHsBjb2Sb-SkkJRznf9uYyvVLrfAE1Px4-u-iL2Dv7GRYjT9OPj-DWz5fTsWcB7C7WqztcwRcK3XYONYvaMomvA
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Identification+and+functional+consequences+of+a+recurrent+NLRP12+missense+mutation+in+periodic+fever+syndromes&rft.jtitle=Arthritis+and+rheumatism&rft.au=J%C3%A9ru%2C+Isabelle&rft.au=Le+Borgne%2C+Ga%C3%ABlle&rft.au=Cochet%2C+Emmanuelle&rft.au=Hayrapetyan%2C+Hasmik&rft.date=2011-05-01&rft.issn=0004-3591&rft.eissn=1529-0131&rft.volume=63&rft.issue=5&rft.spage=1459&rft.epage=1464&rft_id=info:doi/10.1002%2Fart.30241&rft.externalDBID=n%2Fa&rft.externalDocID=10_1002_art_30241
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0004-3591&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0004-3591&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0004-3591&client=summon